Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Aug;125(4):601-610.
doi: 10.1038/s41416-021-01417-7. Epub 2021 May 26.

The risk of contralateral breast cancer: a SEER-based analysis

Vasily Giannakeas #  1   2   3 , David W Lim #  1 , Steven A Narod  4   5   6
Affiliations
Comparative Study

The risk of contralateral breast cancer: a SEER-based analysis

Vasily Giannakeas et al. Br J Cancer. 2021 Aug.

Abstract

Background: We sought to estimate the annual risk and 25-year cumulative risk of contralateral breast cancer among women with stage 0-III unilateral breast cancer.

Methods: We identified 812,851 women with unilateral breast cancer diagnosed between 1990 and 2015 in the SEER database and followed them for contralateral breast cancer for up to 25 years. Women with a known bilateral mastectomy were excluded. We calculated the annual risk of contralateral breast cancer by age at diagnosis, by time since diagnosis and by current age. We compared risks by ductal carcinoma in situ (DCIS) versus invasive disease, by race and by oestrogen receptor (ER) status of the first cancer.

Results: There were 25,958 cases of contralateral invasive breast cancer diagnosed (3.2% of all patients). The annual risk of contralateral breast cancer over the 25-year follow-up period was 0.37% and the 25-year actuarial risk of contralateral invasive breast cancer was 9.9%. The annual risk varied to a small degree by age of diagnosis, by time elapsed since diagnosis and by current age. The 25-year actuarial risk was similar for DCIS and invasive breast cancer patients (10.1 versus 9.9%). The 25-year actuarial risk was higher for black women (12.7%) than for white women (9.7%) and was lower for women with ER-positive breast cancer (9.5%) than for women with ER-negative breast cancer (11.2%).

Conclusions: Women with unilateral breast cancer experience an annual risk of contralateral breast cancer ~0.4% per year, which persists over the 25-year follow-up period.

PubMed Disclaimer

Conflict of interest statement

S.A.N. is an editorial board member of BJC. All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1. 25-Year cumulative incidence of contralateral breast cancer, by age at diagnosis.
The Kaplan-Meier method was used to estimate the 25-year risk of contralateral breast cancer for each age at diagnosis of the primary cancer. The 25-year contralateral breast cancer risk was similar for all ages of diagnosis.
Fig. 2
Fig. 2. Annual risks of contralateral breast cancer, DCIS versus invasive breast cancer patients.
Annual rates of contralateral breast cancer increased slowly with year of follow-up. Rates of contralateral breast cancer were similar for DCIS and invasive breast cancer patients.
Fig. 3
Fig. 3. 25-Year cumulative incidence of contralateral breast cancer, DCIS versus invasive breast cancer patients.
The Kaplan-Meier method was used to estimate the risk of contralateral breast cancer for DCIS and for invasive breast cancer patients. The risk of contralateral breast cancer was similar for DCIS and invasive breast cancer patients.
Fig. 4
Fig. 4. Annual risks of contralateral breast cancer, by ER status (invasive breast cancer patients only).
Annual rates of contralateral breast cancer since diagnosis were calculated by ER status among women with invasive breast cancer. Women with ER-positive breast cancer had a lower annual rate of contralateral breast cancer in the first 10 years of follow-up, compared to women with ER-negative breast cancer. Beyond 10 years from diagnosis, the rate of contralateral breast cancer was similar in both groups.
See this image and copyright information in PMC

References

    1. Zhang B, Coopey SB, Gadd MA, Hughes KS, Chang DC, Oseni TO. Trends in unilateral and contralateral prophylactic mastectomy use in ductal carcinoma in situ of the breast: patterns and predictors. Ann. Surg. Oncol. 2019;26:3863–3873. doi: 10.1245/s10434-019-07628-w. - DOI - PubMed
    1. Nash R, Goodman M, Lin CC, Freedman RA, Dominici LS, Ward K, et al. State variation in the receipt of a contralateral prophylactic mastectomy among women who received a diagnosis of invasive unilateral early-stage breast cancer in the United States, 2004-2012. JAMA Surg. 2017;152:648–657. doi: 10.1001/jamasurg.2017.0115. - DOI - PMC - PubMed
    1. Wang T, Baskin A, Dossett LA. Deimplementation of the choosing wisely recommendations for low-value breast cancer surgery: a systematic review. JAMA Surg. 2020;155:759–770. doi: 10.1001/jamasurg.2020.0322. - DOI - PMC - PubMed
    1. Findlay-Shirras L, Lima I, Smith G, Clemons M, Arnaout A. Canada follows the US in the rise of bilateral mastectomies for unilateral breast cancer: a 23-year population cohort study. Breast Cancer Res. Treat. 2021;185:517–525. doi: 10.1007/s10549-020-05965-z. - DOI - PubMed
    1. Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst. Rev. 2018;4:CD002748. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding